ArticleCell reports2016
Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 230 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
230citing papers in PubMed, 4 pooled it
36.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
230 citing papers in PubMed, 4 syntheses or guidelines pooled it, 378 citations in OpenAlex.
- SNMMI/EANM/ACNM Procedure Standard/Procedure Guideline on the Use of Molecular Imaging for Renal Mass Characterization.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Guideline
- New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Guideline
- Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers: III: Molecular Pathology of Kidney Cancer.The American journal of surgical pathology · 2020Guideline
- Obesity and renal cell carcinoma risk by histologic subtype: A nested case-control study and meta-analysis.Cancer epidemiology · 2018Pooled it
- Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma.Nature communications · 2021Trial
- Fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinoma.Nature communications · 2026Article
- Article
- [Molecular characteristics for poor prognosis related renal cell carcinoma with lymph metastases].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026Article
- DBCL-DFNet: Dual-Branch Contrastive Learning for Multi-Omics Dynamic Fusion.Entropy (Basel, Switzerland) · 2026Article
- Gamma-aminobutyric acid transaminase mediates tumor suppression in renal cell carcinoma through the cGAS-STING-interferon-β axis.Scientific reports · 2026Article
- Prognostic Role of Global DNA Methylation in Renal Cancer Reveals Decitabine Treatment Benefit.Current medicinal chemistry · 2026Article
- Artificial intelligence in genitourinary pathology.Histopathology · 2026Review
- Renal Cell Carcinoma Texture Analysis With the KiTS23 Dataset: A Retrospective Study.Advances in urology · 2026Article
- Molecular and therapeutic landscape of non-clear cell renal carcinoma.Nature reviews. Urology · 2025Review
- Comparative Transcriptomics Study of Curcumin and Conventional Therapies in Translocation, Clear Cell, and Papillary Renal Cell Carcinoma Subtypes.International journal of molecular sciences · 2025Article
- Article
- Integrative Analysis of Immune- and Metabolism-Related Genes Identifies Robust Prognostic Signature and PYCR1 as a Carcinogenic Regulator in Clear Cell Renal Cell Carcinoma.International journal of molecular sciences · 2025Article
- Autosomal Dominant Polycystic Kidney Disease-Related Multifocal Renal Cell Carcinoma: A Narrative Iconographic Review.International journal of molecular sciences · 2025Review
- TFE3 fusion oncoprotein condensates drive transcriptional reprogramming and cancer progression in translocation renal cell carcinoma.Cell reports · 2025Article
- Exploiting NRF2-ARE pathway activation in papillary renal cell carcinoma.International journal of cancer · 2025Article
170 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors at 15 institutions in 3 countries.
Fengju ChenDan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Yiqun ZhangDan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Yasin ŞenbabaoğluComputational Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Giovanni CirielloDepartment of Computational Biology, University of Lausanne, 1015 Lausanne, Switzerland.
Lixing YangDepartment of Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA.
Ed ReznikComputational Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Brian ShuchDepartment of Urology, Yale School of Medicine, New Haven, CT 06520, USA.
Goran MicevicDepartment of Dermatology, Yale University, New Haven, CT 06510, USA; Department of Pathology, Yale University, New Haven, CT 06510, USA.
Guillermo De VelascoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Eve ShinbrotHuman Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA.
Michael S NobleThe Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA.
Yiling LuDepartment of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Kyle R CovingtonHuman Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA.
Liu XiHuman Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA.
Jennifer A DrummondHuman Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA.
Donna MuznyHuman Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA.
Hyojin KangDepartment of Convergence Technology Research, Korea Institute of Science and Technology Information (KAIST), Daejeon 305-806, Korea.
Junehawk LeeDepartment of Convergence Technology Research, Korea Institute of Science and Technology Information (KAIST), Daejeon 305-806, Korea; Department of Bio and Brain Engineering, KAIST, Daejeon 305-806, Korea.
Pheroze TamboliDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Victor ReuterDepartment of Pathology, Memorial Sloan-Kettering Cancer, New York, NY 10065, USA.
Carl Simon ShelleyDepartment of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53726, USA.
Benny A KaipparettuDan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.
Donald P BottaroUrologic Oncology Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Andrew K GodwinDepartment of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA.
Richard A GibbsHuman Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.
Gad GetzThe Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Raju KucherlapatiDepartment of Genetics, Harvard Medical School, Boston, MA 02115, USA; Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Peter J ParkDepartment of Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA.
Chris SanderComputational Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Elizabeth P HenskeThe Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA; Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Jane H ZhouDepartment of Pathology and Laboratory Medicine, Tufts Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA.
David J KwiatkowskiThe Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA; Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Thai H HoDivision of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ 85054, USA.
Toni K ChoueiriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
James J HsiehHuman Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Rehan AkbaniDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Gordon B MillsDepartment of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
A Ari HakimiDepartment of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
David A WheelerHuman Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.
Chad J CreightonDan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA; Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address: creighto@bcm.edu.
Baylor College of Medicine · USMemorial Sloan Kettering Cancer Center · USThe University of Texas MD Anderson Cancer Center · USBroad Institute · USDana-Farber Cancer Institute · USHarvard University · USKorea Advanced Institute of Science and Technology · KRYale University · USBrigham and Women's Hospital · USMayo Clinic in Arizona · USNational Cancer Institute · USTufts University · USUniversity of Kansas Medical Center · USUniversity of Lausanne · CHUniversity of Wisconsin–Madison · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MThe Human Genome Sequencing CenterU54HG003273 · NHGRI · BAYLOR COLLEGE OF MEDICINE · PI GIBBS, RICHARD A · 2004 to 2015
$341.3MTumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MWomen's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3MTumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI DAVID R ROWLEY · 2007 to 2026
$73.9MTreating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Wanling Xie · 2003 to 2026
$53.4MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007205 · NIGMS · YALE UNIVERSITY · PI KAZMIERCZAK, BARBARA I · 1985 to 2019
$42.9MTransgenic & Gene-Targeting Shared ResourceP30CA168524 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI NICOLE L NOLLEN · 2012 to 2026
$40.1MTuberous Sclerosis-Pathway and PathogenesisP01CA120964 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI David J. Kwiatkowski · 2007 to 2026
$35.9MTargeting the PI3K Signaling Pathway in Endometrial CarcinomaP50CA098258 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BODURKA, DIANE · 2003 to 2020
$32.0MHarvard Genome Characterization CenterU24CA144025 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI KUCHERLAPATI, RAJU S. · 2009 to 2016
$14.0MThe BCM Tumor Genome Characterization CenterU24CA143843 · NCI · BAYLOR COLLEGE OF MEDICINE · PI GIBBS, RICHARD A, WHEELER, DAVID ANDREW · 2009 to 2013
$9.5MNCI NIH HHS CA125123NCI NIH HHS F30 CA196089NCI NIH HHS P01 CA120964NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA015083NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA125123NCI NIH HHS P30 CA168524NCI NIH HHS P50 CA098258NCI NIH HHS P50 CA101942NCI NIH HHS R21 CA173150NCI NIH HHS R21 CA179720NCI NIH HHS R21 CA191687NCI NIH HHS U24 CA143843NCI NIH HHS U24 CA144025NHGRI NIH HHS U54 HG003273NIGMS NIH HHS T32 GM007205
Abstract
On the basis of multidimensional and comprehensive molecular characterization (including DNA methalylation and copy number, RNA, and protein expression), we classified 894 renal cell carcinomas (RCCs) of various histologic types into nine major genomic subtypes. Site of origin within the nephron was one major determinant in the classification, reflecting differences among clear cell, chromophobe, and papillary RCC. Widespread molecular changes associated with TFE3 gene fusion or chromatin modifier genes were present within a specific subtype and spanned multiple subtypes. Differences in patient survival and in alteration of specific pathways (including hypoxia, metabolism, MAP kinase, NRF2-ARE, Hippo, immune checkpoint, and PI3K/AKT/mTOR) could further distinguish the subtypes. Immune checkpoint markers and molecular signatures of T cell infiltrates were both highest in the subtype associated with aggressive clear cell RCC. Differences between the genomic subtypes suggest that therapeutic strategies could be tailored to each RCC disease subset.
Indexed as
GenomicsBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsCarcinoma, Renal CellChromatinGene Expression ProfilingHumansKidney NeoplasmsMicroRNAsMutationPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRNA, MessengerSignal TransductionSurvival RateTOR Serine-Threonine KinasesBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsChromatinMicroRNAsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRNA, MessengerTFE3 protein, humanTOR Serine-Threonine Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.